Akebia Therapeutics, Inc. (AKBA)
Market Cap | 274.28M |
Revenue (ttm) | 194.62M |
Net Income (ttm) | -51.93M |
Shares Out | 209.37M |
EPS (ttm) | -0.28 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 930,768 |
Open | 1.350 |
Previous Close | 1.370 |
Day's Range | 1.310 - 1.350 |
52-Week Range | 0.780 - 2.480 |
Beta | 0.84 |
Analysts | Strong Buy |
Price Target | 4.67 (+255.13%) |
Earnings Date | May 6, 2024 |
About AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult pa... [Read more]
Financial Performance
In 2023, AKBA's revenue was $194.62 million, a decrease of -33.46% compared to the previous year's $292.48 million. Losses were -$51.93 million, -44.89% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for AKBA stock is "Strong Buy." The 12-month stock price forecast is $4.67, which is an increase of 255.13% from the latest price.
News
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , April 2, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, grante...
U.S. FDA approves Akebia's anemia drug
The U.S. Food and Drug Administration approved Akebia Therapeutics' drug to treat anemia caused by chronic kidney disease in dialysis patients, the drugmaker said on Wednesday.
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia Akebia's Launch Strategy Developed to Drive Toward a Potential New Oral Standard of Care Company to Host Conference Ca...
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Potential vadadustat U.S. approval on PDUFA date of March 27, 2024 Strengthened balance sheet with $55.0 million term loan financing and $26.0 million in proceeds from ATM Reported 2023 Auryxia (ferr...
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to...
Akebia Secures $55 Million Term Loan Financing
Strengthens Balance Sheet Ahead of Potential Vadadustat Approval on March 27, 2024 CAMBRIDGE, Mass. , Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical com...
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
CAMBRIDGE, Mass. , Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, toda...
Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 20, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to...
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
CAMBRIDGE, Mass. , Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Akebia to host conference call at 8:00 a.m. ET Vadadustat NDA assigned a PDUFA date of March 27, 2024 Vadadustat approved in 36 countries, including Australia and Taiwan Akebia strengthens cash positi...
Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors
Company Strengthens Cash Position in Advance of Potential Vadadustat Launch CAMBRIDGE, Mass. , Nov. 2, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company wit...
Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on November 8 th at 8:00 a.m. ET CAMBRIDGE, Mass.
Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
March 27, 2024 Set as User Fee Goal Date CAMBRIDGE, Mass. , Oct. 25, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives...
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023
CAMBRIDGE, Mass. , Oct. 18, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod...
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
CAMBRIDGE, Mass. , Sept. 28, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to...
Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
CAMBRIDGE, Mass. , Sept. 26, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that Australia's Therapeutic Goods Administration (TGA) has granted approval for Vafseo® (...
Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass. , Sept. 6, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...
Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Akebia to host conference call on August 25, 2023 at 9:00 a.m. ET Expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis in Q3 2023 Reports Auryxia® ...
Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023
Akebia Received Type A Meeting Minutes from the FDA CAMBRIDGE, Mass. , Aug. 24, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better...
Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on August 25 th at 9:00 a.m. ET CAMBRIDGE, Mass.
Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023
Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing CAMBRIDGE, Mass. , Aug. 17, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical co...
Akebia Therapeutics Provides Update on Form 10-Q Filing
Akebia announces late filing of its second quarter earnings and Form 10-Q Akebia reaffirms 2023 net product revenue guidance of $175 - $180 million Akebia believes its cash resources as of June 30, 20...
Akebia Therapeutics to Present at the H.C. Wainwright Kidney Conference
CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...
Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
CAMBRIDGE, Mass. , July 18, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod...
Akebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis Patients
CAMBRIDGE, Mass. , June 29, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today...